

CITATION REPORT

List of articles citing

Histologic muscular history in steroid-treated and untreated patients with Duchenne dystrophy

DOI: 10.1212/wnl.00000000000002147
Neurology, 2015, 85, 1886-93.

Source: <https://exaly.com/paper-pdf/62465046/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
33	Simvastatin offers new prospects for the treatment of Duchenne muscular dystrophy. <i>Rare Diseases (Austin, Tex)</i> , 2016 , 4, e1156286		7
32	Validation of ultrasonography for non-invasive assessment of diaphragm function in muscular dystrophy. <i>Journal of Physiology</i> , 2016 , 594, 7215-7227	3.9	19
31	Histological effects of givinostat in boys with Duchenne muscular dystrophy. <i>Neuromuscular Disorders</i> , 2016 , 26, 643-649	2.9	96
30	Diagnosis of Duchenne Muscular Dystrophy in Italy in the last decade: Critical issues and areas for improvements. <i>Neuromuscular Disorders</i> , 2017 , 27, 447-451	2.9	24
29	Elevated phosphodiester and T levels can be measured in the absence of fat infiltration in Duchenne muscular dystrophy patients. <i>NMR in Biomedicine</i> , 2017 , 30, e3667	4.4	31
28	Pharmacological inhibition of REV-ERB stimulates differentiation, inhibits turnover and reduces fibrosis in dystrophic muscle. <i>Scientific Reports</i> , 2017 , 7, 17142	4.9	17
27	Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD). <i>Neuropathology and Applied Neurobiology</i> , 2018 , 44, 449-462	5.2	17
26	One-year follow up of three Italian patients with Duchenne muscular dystrophy treated with ataluren: is earlier better?. <i>Therapeutic Advances in Neurological Disorders</i> , 2018 , 11, 1756286418809588	6.6	6
25	Hippo signaling pathway is altered in Duchenne muscular dystrophy. <i>PLoS ONE</i> , 2018 , 13, e0205514	3.7	20
24	Purkinje cell COX deficiency and mtDNA depletion in an animal model of spinocerebellar ataxia type 1. <i>Journal of Neuroscience Research</i> , 2018 , 96, 1576-1585	4.4	6
23	Consensus on the diagnosis, treatment and follow-up of patients with Duchenne muscular dystrophy. <i>Neurologia (English Edition)</i> , 2019 , 34, 469-481	0.4	1
22	Imaging respiratory muscle quality and function in Duchenne muscular dystrophy. <i>Journal of Neurology</i> , 2019 , 266, 2752-2763	5.5	9
21	Eteplirsen Treatment Attenuates Respiratory Decline in Ambulatory and Non-Ambulatory Patients with Duchenne Muscular Dystrophy. <i>Journal of Neuromuscular Diseases</i> , 2019 , 6, 213-225	5	50
20	Targeting angiogenesis in Duchenne muscular dystrophy. <i>Cellular and Molecular Life Sciences</i> , 2019 , 76, 1507-1528	10.3	22
19	Detection of collagens by multispectral optoacoustic tomography as an imaging biomarker for Duchenne muscular dystrophy. <i>Nature Medicine</i> , 2019 , 25, 1905-1915	50.5	60
18	Consensus on the diagnosis, treatment and follow-up of patients with Duchenne muscular dystrophy. <i>Neurologia</i> , 2019 , 34, 469-481	1.4	5
17	The SINE Compound KPT-350 Blocks Dystrophic Pathologies in DMD Zebrafish and Mice. <i>Molecular Therapy</i> , 2020 , 28, 189-201	11.7	11

16	Therapies that are available and under development for Duchenne muscular dystrophy: What about lung function?. <i>Pediatric Pulmonology</i> , 2020 , 55, 300-315	3.5	4
15	Orbicularis Oculi Morphological Alterations in Affected and Nonaffected Sides in Hemifacial Spasm. <i>Journal of Neuro-Ophthalmology</i> , 2020 , 40, 193-197	2.6	1
14	Magnetic Resonance Imaging Studies in Duchenne Muscular Dystrophy: Linking Findings to the Physical Therapy Clinic. <i>Physical Therapy</i> , 2020 , 100, 2035-2048	3.3	0
13	MR biomarkers predict clinical function in Duchenne muscular dystrophy. <i>Neurology</i> , 2020 , 94, e897-e905	3.5	24
12	Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOVI Trial. <i>Journal of Neuromuscular Diseases</i> , 2021 , 8, 989-1001	5	13
11	A semiautomated measurement of muscle fiber size using the Imaris software. <i>American Journal of Physiology - Cell Physiology</i> , 2021 , 321, C615-C631	5.4	5
10	Epigenetic modifications in muscle regeneration and progression of Duchenne muscular dystrophy. <i>Clinical Epigenetics</i> , 2021 , 13, 13	7.7	6
9	Effect of exercise on telomere length and telomere proteins expression in mdx mice. <i>Molecular and Cellular Biochemistry</i> , 2020 , 470, 189-197	4.2	4
8	Intermittent glucocorticoid steroid dosing enhances muscle repair without eliciting muscle atrophy. <i>Journal of Clinical Investigation</i> , 2017 , 127, 2418-2432	15.9	59
7	Dystrophinopathies. 2020 , 413-436		
6	Description of Osmolyte Pathways in Maturing Mice Reveals Altered Levels of Taurine and Sodium/Myo-Inositol Co-Transporters.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	1
5	Muscle histological changes in a large cohort of patients affected with Becker muscular dystrophy.. <i>Acta Neuropathologica Communications</i> , 2022 , 10, 48	7.3	0
4	Characterization of patients with Becker muscular dystrophy by histology, magnetic resonance imaging, function, and strength assessments.. <i>Muscle and Nerve</i> , 2021 ,	3.4	2
3	MicroRNAs as serum biomarkers in Becker muscular dystrophy. <i>Journal of Cellular and Molecular Medicine</i> ,	5.6	
2	Hedgehog signaling acts as cell fate determinant during adult tissue repair.		2
1	Immunofluorescence signal intensity measurements as a semi-quantitative tool to assess sarcoglycan complex expression in muscle biopsy. 2022 , 66,		0